Introduction
Intraductal proliferative lesions refer to a diverse set of epithelial proliferations that vary in cellular and structural characteristics. These lesions are associated with an elevated risk, although the degree of risk varies for the subsequent development of infiltrating carcinoma.
What Are the Classification of Intraductal Proliferative Lesions?
The classification of intraductal proliferative breast lesions typically consists of three categories: ordinary ductal hyperplasia (UDH), atypical ductal hyperplasia (ADH), and ductal carcinoma in situ (DCIS).
-
Ordinary Ductal Hyperplasia(UDH): In typical hyperplasia (the prevailing type of hyperplasia), the actively dividing cells appear normal when observed via a microscope. Women diagnosed with typical hyperplasia have approximately double the risk of developing breast cancer compared to women without a proliferative breast disease.
-
Atypical Hyperplasia (ADH): Atypical hyperplasia is characterized by abnormal-looking proliferating (dividing) cells. Ordinary hyperplasia is more prevalent than atypical hyperplasia. The risk of breast cancer in women with atypical hyperplasia is approximately three to five times that of women without a proliferative breast condition.
-
Ductal Carcinoma In Situ (DCIS): It is also known as intraductal carcinoma or stage 0 breast cancer, which refers to a non-invasive form of breast cancer. DCIS refers to a type of breast cancer that is not invasive or pre-invasive. These cells that form the lining of the ducts have transformed into cancerous cells, but they have not extended beyond the duct walls to invade the surrounding breast tissue.
Breast intraductal proliferative lesions (IPLs) are limited to the duct-lobular system and start from the terminal duct-lobular unit (TDLU), the breast's epithelial structures. These structures generate milk during lactation, serving as the main anatomical source of most breast malignancies and their predecessors. IPLs have different cellular and architectural patterns of proliferation. They are marked by increased cells not attached to the basement membrane. This changes the usual unit structure of the breast and makes it stretch out without adding to the number of cells.
It is known that TDLU can cause both a lobular (irregular cells start to grow in the milk glands lobules in the breast) and a ductal (there are strange cells in a breast milk stream; it is thought to be the first type of breast cancer. DCIS is non-invasive, meaning it has not grown outside the milk duct. It is not likely to become an invasive, though) type of epithelial growth. Intraductal proliferations have a lot of different cytological (cell alteration) and architectural features, while the first type is uniform.
What Is the Ductal Intraepithelial Neoplasia System?
The ductal intraepithelial neoplasia system is a disorder in which abnormal cells are identified in the lining of a mammary duct (milk duct). When these abnormal cells develop into cancer and spread to other breast tissues outside of the duct, ductal intraepithelial neoplasia may raise the risk of breast cancer.
There are two types of ductal intraepithelial neoplasia, atypical ductal hyperplasia and ductal cancer in situ:
-
Atypical Hyperplasia: Atypical hyperplasia is a pre-neoplastic disease that impacts breast cells. Atypical hyperplasia refers to the buildup of aberrant cells in the milk ducts and lobules of the breast. Atypical hyperplasia elevates the likelihood of developing breast cancer. Suppose atypical hyperplasia cells concentrate in the milk ducts or lobules and undergo further abnormal changes. In that case, this can progress to non-invasive breast cancer (carcinoma in situ) or invasive breast cancer throughout the lifetime.
-
Ductal Carcinoma in Situ: Ductal carcinoma in situ (DCIS) refers to the existence of atypical cells within a milk duct located in the breast. It is the initial stage of breast cancer. DCIS is characterized by its non-invasive nature, indicating that it has not extended beyond the milk duct and poses a minimal risk of developing invasiveness.
A classification system known as DIN (ductal intraepithelial neoplasia) is used to grade the cancer encompassing intraductal proliferative lesions. Based on the DIN1a classification in this system, the likelihood of developing an invasive malignancy is 1.5 to 2 times greater for individuals with intraductal hyperplasia than for the general population.
What Is the Pathological Process?
-
Intraductal proliferative breast lesions are limited to the duct-lobular system and originate from the terminal duct-lobular unit. They exhibit various architectural and cytological patterns of proliferation and an elevated quantity of cells oriented at a right angle to the basement membrane, leading to expansion and complete modification of the typical structural composition of the breast.
-
One can observe the multifocal and discontinuous characteristics of intraductal hyperplasia inside a single duct by examining consecutive sections. Moreover, an expansion of the impacted glandular structure, characterized by an increase in length and a larger diameter, is frequently observed.
-
Intraductal hyperplasia can occur in women of all age groups, and no distinct clinical characteristics are exclusively linked to intraductal hyperplasia. The alterations resulting from the growth of epithelial cells in individual ducts (as well as in many branches of a ductal system) are very small and cannot be felt.
-
A significant outcome of the lack of clinical signs is the inability to ascertain the duration of these lesions. As a result, this is seen as a potential cause of presumption when evaluating the precancerous importance of proliferative lesions in particular patients.
-
Intraductal hyperplasia typically manifests as a non-specific palpable region commonly characterized as thickening of the breast tissue. The non-specific mammographic signs of these changes include parenchymal deformation, modified duct patterns, non-palpable masses, calcification, and breast asymmetry.
What Are the Management of Conditions?
An essential aspect of managing this condition is accurately differentiating between intraductal hyperplasia and intraductal cancer. The primary issue revolves around the potential risk of developing cancer, which is higher in the presence of atypia compared to when hyperplasia falls within the normal area.
-
Patients diagnosed with intraductal hyperplasia are advised to actively engage in a follow-up regimen that encompasses self-examination, medical evaluation, and mammography. Women with atypia and specific risk factors, such as a family history of breast cancer, typically have more regular examinations scheduled.
-
Tamoxifen, an effective inhibitor of estrogen, was also employed to reduce the likelihood of cancer formation—the reduction in the development of future invasive cancer in the treated women with atypical intraductal hyperplasia.
Conclusion
The proposed criteria for intraductal proliferative lesions are complex regarding diagnosis and repeatability. The occurrence of certain entities in practice remains ambiguous to exacerbate the controversy. The multitude of molecular findings reported in multiple studies demonstrates the complicated nature of morphological complexity. Some analyses of different clinical circumstances provide important information about their properties and development prospects.
The DIN system sorts different cases into groups that do not always show signs of invasive ductal carcinoma (IDC). Understanding the diagnostic criteria is crucial for correctly identifying and categorizing epithelial proliferative lesions of the breast. This knowledge is important for determining the appropriate management and assessing the risk of developing later invasive breast cancer (IBC).
